CACNB2

(redirected from CAB2)

CACNB2

A gene on chromosome 10p12 that encodes a beta subunit of a voltage-dependent L-type calcium channel which, like other beta subunits, contributes to calcium-channel function by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation.

Molecular pathology
The gene product was first identified as an antigen target in Lambert-Eaton myasthenic syndrome, an autoimmune disorder. CACNB2 mutations are associated with Brugada symdrome, type 4.
References in periodicals archive ?
Millennium is also developing, in collaboration with XOMA Ltd, MLN01, a humanized monoclonal antibody, which is being investigated for cardiovascular uses, and CAB2, a recombinant fusion protein that inhibits complement activation, currently in preclinical trials for the treatment of reperfusion injury.
on CAB2 and MLN2201 for certain vascular inflammation indications (preclinical and Phase I, respectively).
on two biotherapeutic agents, CAB2 and MLN01, for certain vascular inflammation indications (preclinical); and with Onyx Pharmaceuticals, Inc.
lower service revenues from Onyx and Baxter; -- higher research and development expenses related to clinical testing of Raptiva(TM) in psoriasis, rheumatoid arthritis and psoriatic arthritis, and MLN01 and CAB2, subject to successful completion of preclinical testing; and -- higher marketing, general and administrative expenses, as savings on litigation expense are expected to be more than offset by increased marketing expenses related to pre-launch activities for Raptiva(TM).
Year-to-date research and development expenses increased 16%, reflecting ongoing development spending on Raptiva(TM) (efalizumab, formerly Xanelim(TM)) for testing in psoriasis and rheumatoid arthritis, as well as on MLN01, CAB2 and ONYX-015.